Key Highlights

  • City Therapeutics priced an upsized IPO of 11,111,111 shares at $18.00, raising $200.0 million in gross proceeds before costs.
  • Early CITY-FXI data showed Factor XI knockdown of 85% three weeks after a single 150 mg dose in healthy volunteers.
  • The company estimates cash and cash equivalents of about $141.9 million at September 30, 2026, a preliminary, unaudited figure.
  • Net loss for the six months ended June 30, 2026 was $53.4 million; the accumulated deficit was $142.5 million.

City Therapeutics (NASDAQ:CTY) shares were trading near their 52-week high at USD 21.72 on October 19, 2026, down 3.04%. The Cambridge, Massachusetts company, founded in July 2023, develops RNA interference (RNAi) medicines. It announced the pricing of an upsized initial public offering on October 15 and filed its final prospectus the next day. One program, CITY-FXI, is in a Phase 1 trial, and the company expects two more candidates to begin human studies in late 2026. The same prospectus describes a record of losses and a need for further capital.

A $200 million raise and a stated runway into late 2028

City sold 11,111,111 shares at $18.00, all offered by the company, for gross proceeds of $199,999,998. Underwriters hold a 30-day option on up to 1,666,666 more shares. Net proceeds are estimated at about $181.5 million, or $209.4 million if the option is exercised in full, and 51,721,168 shares are expected to be outstanding after the offering.

Management plans to apply the net proceeds and existing cash mainly to CITY-FXI (about $30.0 million), CITY-RBP4 ($20.0 million), CITY-TFR2 ($40.0 million) and the City Platform ($70.0 million). Cash, cash equivalents and restricted cash were $172.1 million at June 30. The company estimates cash and cash equivalents of about $141.9 million at September 30, a preliminary, unaudited figure. It believes existing cash plus the net proceeds will fund its needs into late 2028, and it says it will require substantial additional capital.

Three RNAi programs at three different stages

CITY-FXI, a GalNAc-conjugated siRNA aimed at Factor XI for thromboembolic diseases, entered a Phase 1 trial in 2026. Data from the first three single-ascending-dose cohorts in healthy volunteers showed Factor XI knockdown above 60% after a 15 mg subcutaneous dose, close to 80% after 50 mg, and 85% three weeks after 150 mg. The company calls the drug generally well tolerated and cautions that early results may not predict later outcomes.

CITY-RBP4 targets Stargardt disease and geographic atrophy, and the company filed an application in mid-2026 to open a Phase 1 trial. CITY-TFR2 is preclinical and aimed at anemia of chronic disease, initially anemia associated with myelofibrosis.

Two research collaborations sit alongside the pipeline: Bausch + Lomb, signed in July 2024 for one retinal target, and Biogen, signed in May 2025 for neurodegenerative disease. Collaboration revenue was $6.4 million for the six months ended June 30, up from $5.6 million.

Losses, dilution and other cautions in the prospectus

Net loss was $27.8 million in 2024 and $58.5 million in 2025. For the six months ended June 30, 2026 it was $53.4 million, against $24.3 million a year earlier, with research and development expense up to $46.3 million from $24.4 million. The accumulated deficit was $142.5 million, and the company expects losses to continue.

City has no approved products and has not completed a clinical trial. It says its platform approach is unproven, depends heavily on its three lead candidates, relies on third-party manufacturers and uses in-licensed technology, including a royalty-bearing license from Ohio State Innovation Foundation. In connection with the offering, convertible preferred stock converts into 28,848,641 common shares and a Biogen convertible note into 2,133,788 shares. Options for 5,404,513 shares were outstanding at June 30 at a weighted average exercise price of $1.97, and they are excluded from the 51,721,168 share estimate.

Milestones the company expects through late 2027

In late 2026 the company expects additional CITY-FXI Phase 1 data, a CITY-RBP4 Phase 1 start, a CITY-TFR2 investigator-initiated trial in China, an IND or equivalent filing for CITY-TFR2, and Bausch + Lomb's development candidate selection. A CITY-TFR2 Phase 1/2 study is expected in early 2027. Mid-2027 is the target for initial CITY-RBP4 data, CITY-TFR2 trial data and a CITY-FXI Phase 2 start in total knee arthroplasty. Late 2027 includes a planned CITY-RBP4 Phase 2 in geographic atrophy and Biogen's candidate selection. These are expectations, not completed events.